PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Drug Development Department, DITEP, Gustave Roussy, Villejuif, France; Université Paris Saclay, Université Paris-Sud, Faculté de Médecine, Le Kremlin Bicêtre, France; ATIP-Avenir Group, Inserm Unit U981, Gustave Roussy, Villejuif, France. Electronic address: m.t.m.reinders@umcutrecht.nl.\', \'Drug Development Department, DITEP, Gustave Roussy, Villejuif, France; Université Paris Saclay, Université Paris-Sud, Faculté de Médecine, Le Kremlin Bicêtre, France.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0959-8049(20)30392-010.1016/j.ejca.2020.07.009
?:doi
?:hasPublicationType
?:journal
  • European journal of cancer (Oxford, England : 1990)
is ?:pmid of
?:pmid
?:pmid
  • 32805640
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management?
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32805640>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32805640>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all